Spelling suggestions: "subject:"overexpression"" "subject:"verexpression""
61 |
Επίδραση της υπερέκφρασης της Geminin στη δημιουργία διαφόρων τύπων νευρώνων κατά την ανάπτυξη του εγκεφαλικού φλοιού / Effect of the overexpression of Geminin in the creation of various types of neurons during the development of cerebral cortexΔημοπούλου, Αγγελική 05 February 2015 (has links)
Η δημιουργία του εγκεφαλικού φλοιού στηρίζεται στη διαδοχική εμφάνιση πληθυσμών προγονικών νευρώνων, οι οποίοι δίνουν γένεση σε νευρικά και γλοιακά κύτταρα. Κατά την νευρογένεση όλοι οι νευρώνες του εγκεφαλικού φλοιού προέρχονται από το νευροεπιθήλιο που βρίσκεται δίπλα από τις πλευρικές κοιλίες. Τα νευροεπιθηλιακά κύτταρα αρχικά διαιρούνται με σκοπό την δημιουργία ικανού αριθμού πρόδρομων κυττάρων που θα δώσουν γένεση στον αναπτυσσόμενο φλοιό. Αργότερα, τα κύτταρα αυτά, διαφοροποιούνται προς τις άλλες κατηγορίες πρόδρομων κυττάρων και προς τους διαφοροποιημένους νευρώνες.
Η πρωτεΐνη Geminin έχει προταθεί ως ένα μόριο που ρυθμίζει τόσο τον κυτταρικό πολλαπλασιασμό όσο και την κυτταρική διαφοροποίηση.
Προκειμένου να διερευνηθεί ο ρόλος της πρωτεΐνης Geminin in vivo στη δημιουργία νευρώνων, πραγματοποιήθηκαν πειράματα υπερέκφρασης της Geminin στον αναπτυσσόμενο εγκεφαλικό φλοιό του μυός κατά την Ε14.5 dpc. Τα αποτελέσματα της παρούσας εργασίας δείχνουν ότι η υπερέκφραση της Geminin οδηγεί στην αύξηση του αριθμού των κυττάρων της ανώτερης στοιβάδας και μείωση του αριθμού των κυττάρων της κατώτερης στοιβάδας.
Συνοψίζοντας, τα αποτελέσματά μας προτείνουν ότι η Geminin συμμετέχει στη ρύθμιση του πληθυσμού των φλοιϊκών νευρώνων. / Cortical development is a highly ordered process, involving the timely orchestration of the appearance of different neural progenitor lineages, which succeed one another in order to generate the neurons and glia comprising the cortex.During neurogenesis, the cortical neurons are originated from the neuroepithelium that lies next to the lateral vesicles. At the beginning, neuroepithelial cells divide in order to expand their population and to create the number of progenitor cells that would give rise to the neurons and glia that comprise the cortex.
Geminin has been shown to regulate cell proliferation, fate determination and organogenesis, representing a potential link between these processes.
In order to investigate the in vivo role of Geminin in the creation of the cortical neurons, we performed overexpression experiments with of Geminin in the developing mouse cortex. Our results indicate that overexpression of Geminin in the developing cerebral cortex increases the number of the upper layer cells and reduces the number of the deep layer cells at E14.5 dpc.
Our work suggests that Geminin is a molecule that participates in the regulation of the correct number of cortical progenitors and neurons in the cerebral cortex.
|
62 |
Der Einfluss von NR3C1 und PDK4 auf das Wachstum kolorektaler Tumorzellen / The effect of NR3C1 and PDK4 on the growth of colorectal cancer cellsSchmetzke, Stefanie 02 October 2012 (has links)
No description available.
|
63 |
Development of genetic tools for metabolic engineering of Clostridium pasteurianumPyne, Michael E 21 April 2015 (has links)
Reducing the production cost of industrial biofuels will greatly facilitate their proliferation and co-integration with fossil fuels. The cost of feedstock is the largest cost in most fermentation bioprocesses and therefore represents an important target for cost reduction. Meanwhile, the biorefinery concept advocates revenue growth through complete utilization of by-products generated during biofuel production. Taken together, the production of biofuels from low-cost crude glycerol, available in oversupply as a by-product of bioethanol production, in the form of thin stillage, and biodiesel production, embodies a remarkable opportunity to advance affordable biofuel development. However, few bacterial species possess the natural capacity to convert glycerol as a sole source of carbon and energy into value-added bioproducts. Of particular interest is the anaerobe Clostridium pasteurianum, the only microorganism known to convert glycerol alone directly into butanol, which currently holds immense promise as a high-energy biofuel and bulk chemical. Unfortunately, genetic and metabolic engineering of C. pasteurianum has been fundamentally impeded due to a complete lack of genetic tools and techniques available for the manipulation of this promising bacterium. This thesis encompasses the development of fundamental genetic tools and techniques that will permit extensive genetic and metabolic engineering of C. pasteurianum.
We initiated our genetic work with the development of an electrotransformation protocol permitting high-level DNA transfer to C. pasteurianum together with accompanying selection markers and vector components. The CpaAI restriction-modification system was found to be a major barrier to DNA delivery into C. pasteurianum which we overcame by in vivo methylation of the recognition site (5’-CGCG-3’) using the M.FnuDII methyltransferase. Systematic investigation of various parameters involved in the cell growth, washing and pulse delivery, and outgrowth phases of the electrotransformation procedure significantly elevated the electrotransformation efficiency up to 7.5 × 104 transformants µg-1 DNA, an increase of approximately three orders of magnitude. Key factors affecting the electrotransformation efficiency include cell-wall-weakening using glycine, ethanol-mediated membrane solubilization, field strength of the electric pulse, and sucrose osmoprotection.
Following development of a gene transfer methodology, we next aimed to sequence the entire genome of C. pasteurianum. Using a hybrid approach involving 454 pyrosequencing, Illumina dye sequencing, and single molecule real-time sequencing platforms, we obtained a near-complete genome sequence comprised of 12 contigs, 4,420,100 bp, and 4,056 candidate protein-coding genes with a GC content of 30.0%. No extrachromosomal elements were detected. We provide an overview of the genes and pathways involved in the organism’s central fermentative metabolism.
We used our developed electrotransformation procedure to investigate the use of established clostridial group II intron biology for constructing chromosomal gene knockout mutants of C. pasteurianum. Through methylome analysis of C. pasteurianum genome sequencing data and transformation assays of various vector deletion constructs, we identified a new Type I restriction-modification system that inhibits transfer of vectors harboring group II intron gene knockout machinery. We designated the new restriction system CpaAII and proposed a recognition sequence of 5’-AAGNNNNNCTCC-3’. Overcoming restriction by CpaAII, in addition to low intron retrohoming efficiency, allowed the isolation of a gene knockout mutant of C. pasteurianum with a disrupted CpaAI Type II restriction system. The resulting mutant strain should be efficienty transformed with plasmid DNA lacking M.FnuDII methylation.
Lastly, we investigated the use of plasmid-based gene overexpression and chromosomal gene downregulation to alter gene expression in C. pasteurianum. Using a β-galactosidase reporter gene, we characterized promoters corresponding to the ferredoxin and thiolase genes of C. pasteurianum and show that both promoters permitted high-level, constitutive gene expression. The thiolase promoter was then utilized to drive transcription of an antisense RNA molecule possessing complementarity to mRNA of our β-galactosidase reporter gene. Our antisense RNA system demonstrated 52-58% downregulation of plasmid encoded β-galactosidase activity throughout the duration of growth. In an attempt to perturb the central fermentative metabolism of C. pasteurianum and enhance butanol titers, we prepared several antisense RNA constructs for downregulation of 1,3-propanediol, butyrate, and hydrogen production pathways. The resulting downregulation strains are expected to exhibit drastically altered central fermentative metabolism and product distribution.
Taken together, we have demonstrated that C. pasteurianum is amendable to genetic manipulation through the development of methods for plasmid DNA transfer and gene overexpression, knockdown, and knockout. Further, our genome sequence should provide valuable nucleotide sequence information for the application of our genetic tools. Thus, the genome sequence, electrotransformation method, and associated genetic tools and techniques reported here should promote extensive genetic manipulation and metabolic engineering of this biotechnologically important bacterium.
|
64 |
Δημιουργία ζώων μοντέλων για τη διερεύνηση του in vivo ρόλου της geminin : αδρανοποίηση του γονιδίου σε μύες με τη χρήση ολοδύναμων εμβρυονικών κυττάρων (knockout) και ιστοειδική υπερέκφραση σε διαγονιδιακούς μύεςΚοταντάκη, Πανωραία 16 June 2011 (has links)
Η ανάπτυξη του ανοσοποιητικού συστήματος ξεκινά από πολυδύναμα αρχέγονα αιμοποιητικά κύτταρα, τα οποία διαδοχικά δίνουν γένεση σε ενδιάμεσους πληθυσμούς προγονικών κυττάρων οι οποίοι σταδιακά χάνουν την ικανότητά τους για αυτοανανέωση και τελικά δίνουν γένεση στα πλήρως διαφοροποιημένα κύτταρα της μυελικής και λεμφικής σειράς. Η συγκεκριμένη διαδικασία στηρίζεται στο λεπτό συντονισμό της αυτοανανέωσης, αλλά και της διαφοροποίησης, απαιτεί δε την έκφραση διαφορετικών γονιδίων που σχετίζονται με τη ρύθμιση του κυτταρικού κύκλου, τη μεταγραφική ρύθμιση γονιδίων, αλλά και συμπλόκων αναδιοργάνωσης της δομής της χρωματίνης που εμπλέκονται στη διαφοροποίηση.
Η geminin έχει προταθεί ότι ρυθμίζει την απόφαση ενός κυττάρου για πολλαπλασιασμό ή διαφοροποίηση. Αλληλεπιδρά με μεταγραφικούς παράγοντες, με σύμπλοκα αναδιάταξης της δομής της χρωματίνης, ρυθμίζοντας την έκφραση γονιδίων που ελέγχουν τη νευρωνική διαφοροποίηση. Παράλληλα, δρα σαν αναστολέας του κυτταρικού κύκλου, προσδενόμενη στο παράγοντα αδειοδότησης της αντιγραφής του DNA, CDT1. Στόχος μας ήταν να διερευνήσουμε τον in vivo ρόλο της Geminin στη διαφοροποίηση και τον πολλαπλασιασμό, στο ανοσοποιητικό σύστημα.
Στα πλαίσια της διδακτορικής διατριβής, βασιζόμενοι στο σύστημα Cre-loxP, δημιουργήσαμε μύες που επιτρέπουν την υπό συνθήκη εξάλειψη (knockout) του γονιδίου της geminin, πλαισιώνοντας τα εξώνια 3 και 4 του γονιδίου της με θέσεις loxP. Η στόχευση του γονιδίου και η παρεμβολή των 3 loxP θέσεων πραγματοποιήθηκε σε pc3 εμβρυικά πολυδύναμα κύτταρα μυός, χρησιμοποιώντας κατάλληλο πλασμιδιακό knockout φορέα, που έφερε τη κασέτα επιλογής TKneo. Μετά από ένεση των ορθά ανασυνδυασμένων pc3 κλώνων σε βλαστοκύστεις, τη δημιουργία χιμαιρικών μυών που εκφράζουν την Cre ρεκομπινάση στη γαμετική σειρά, και την επακόλουθη διασταύρωσή τους με μύες αγρίου τύπου, δημιουργήθηκαν ετερόζυγοι μύες για το πλαισιωμένο με loxP θέσεις αλληλόμορφο της Geminin, που παράλληλα έφερε και τη κασέτα επιλογής TKneo («floxed-ΤΚneo»), το πλαισιωμένο με loxP θέσεις αλληλόμορφο της Geminin, που στερούνταν της κασέτας επιλογής TKneo (floxed), καθώς επίσης και το αλληλόμορφο που στερούνταν των εξωνίων 3 και 4 και είναι το πλήρες knockout (ΔGEM ΚΟ -null) αλληλόμορφο). Από διασταυρώσεις ετερόζυγων για το ΔGEM ΚΟ αλληλόμορφο της geminin, δεν προέκυψαν ομόζυγοι μύες για το ΔGEM ΚO αλληλόμορφο (-/-), τόσο μεταγεννητικά όσο και in utero. Η μειωμένη αντιπροσώπευση των ΔGEM+/- μυών σε συνδυασμό με την αύξηση των Thy1-/B220- κυττάρων σε σπλήνα και λεμφαδένες ενήλικων μυών, η σημαντική αύξηση των Thy1+ και ειδικότερα των CD8+ Τ κυττάρων, καθώς επίσης και η αισθητή μείωση των CD4+ Τ κυττάρων του σπλήνα σε ζώα ηλικίας 5 μηνών, προτείνει ένα είδος απλοανεπάρκειας των ετερόζυγων για Geminin μυών. Σε παραπλήσια αποτελέσματα οδηγηθήκαμε και μετά από την ανάλυση των GT KO για το γονίδιο της Geminin (GT) μυών με τη μεθοδολογία της παγίδευσης γονιδίων.
Τα ετερόζυγα GT ζώα διασταυρώθηκαν με ετερόζυγα ζώα για το πλήρες ΚΟ του BRG1 (BRG) και με ετερόζυγα ζώα που υπερεκφράζουν μια επικρατούσα κατασταλτική μορφή του BAF57 (BAFΔΝ, BAF), προκειμένου να διαπιστωθεί εάν υπάρχει γενετική αλληλεπίδραση μεταξύ της Geminin και των μελών του συμπλέγματος αναδιοργάνωσης της δομής της χρωματίνης SWI/SNF, BRG1 και BAF57 που έχει δειχθεί ότι παίζουν σημαντικό ρόλο κατά την ανάπτυξη και διαφοροποίηση του ανοσοποιητικού συστήματος.
Ιστοειδικά, χρησιμοποιώντας την floxedΤΚneo σειρά μυών σε συνδυασμό με την CD2-Cre, που επιτρέπει την εξάλειψη του γονιδίου από το στάδιο των DN κυττάρων του θύμου και μετά, είδαμε ότι η ανάπτυξη του θύμου δεν φαίνεται να επηρεάζεται κατά την απουσία της Geminin, ενώ αντίθετα ο ολικός αριθμός των σπληνοκυττάρων μειώνεται στα FlTKneo/KO;CD2 σε σχέση με τα WT. Μιτωγονική διέγερση με ConA εναιωρήματος σπληνοκυττάρων από FlTKneo/KO;CD2 και WT ζώα, έδειξε ότι τα FlTKneo/KO;CD2 Τ λεμφοκύτταρα αδυνατούν να διαιρεθούν.
Τέλος, έγινε προσπάθεια για ιστοειδική υπερέκφραση στο ανοσοποιητικό σύστημα της ανθρώπινης Geminin συντηγμένης με τη πράσινη φθορίζουσα χρωστική (GFP). Το συγκεκριμένο σύστημα επιτρέπει την υψηλή έκφραση του διαγονιδίου κυρίως στα Τ κύτταρα. Ενώ προέκυψαν ιδρυτές για όλες τις πιο πάνω σειρές τόσο με χαμηλή όσο και με υψηλή ενσωμάτωση του διαγονιδίου, η έκφραση της GFP δεν κατέστη δυνατόν να ανιχνευθεί με FACS.
Συνοψίζοντας, τα αποτελέσματά μας καταδεικνύουν ότι η Geminin είναι ιδιαίτερα σημαντική κατά τα αρχικά στάδια ανάπτυξης του εμβρύου μυός, ενώ ιστοειδικά στο ανοσοποιητικό σύστημα η πλήρης εξάλειψή της δεν έχει καμία επίπτωση στην ανάπτυξη του θύμου αδένα, ενώ αντίθετα στη σπλήνα εμφανίζονται μειωμένοι οι πληθυσμοί των ώριμων CD4 και CD8 Τ λεμφοκυττάρων. Τέλος, φαίνεται να συνεργάζεται με το σύμπλεγμα αναδιοργάνωσης της δομής της χρωματίνης SWI/SNF στη ρύθμιση των CD4 κυττάρων του θύμου αδένα και των CD8 του σπλήνα. / Immune system development initiates from a multipotent hematopoietic stem cell that consecutively generates intermediate progenitors that concomitantly lose their self-renewal ability and finally generate the fully differentiated cells of the myeloid and lymphoid lineage. The whole procedure is based on the fine tuning of the processes of both self-renewal and differentiation, and requires the expression of diverse genes that are implicated in the processes of cell cycle regulation, transcriptional regulation, and are constituents of chromatin remodeling complexes that operate during differentiation.
Geminin has been proposed to control a cell’s decision to proliferate or differentiate. It interacts with transcription factors, with chromatin remodeling complexes, regulating neurospecific gene transcription. At the same time, Geminin acts as a cell cycle inhibitor through direct binding to the DNA licensing factor CDT1. Our goal was to investigate Geminin’s in vivo role in differentiation and cell cycle regulation in the immune system.
In this thesis, using Cre-loxP system, we generated conditional knockout mice for Geminin’s gene, flanking exons 3 and 4 with loxP sites. Gene targeting and the insertion of the three loxP sites was performed in pc3 mouse embryonic stem cells, using a suitable knockout plasmid vector, which bared the TKneo cassette selection marker. Upon injection of the homologously recombined pc3 clones into blastocysts, the generation of chimeric mice that expressed Cre recombinase in their germ line, and their subsequent cross to wild type mice, we were able to generate heterozygote mice for the flanked by loxP sites allele of Geminin that also bared TKneo selection marker (“floxed-TKneo” allele), the flanked by loxP sites allele of Geminin that was deprived of the TKneo selection marker (the floxed allele) and the complete knockout allele of Geminin (ΔGEM KO (null) allele) that was deprived of exons 3 and 4. From ΔGEM+/- intercrosses we didn’t recover any homozygote knockout mice, both postnatally and in utero. The reduced number of the ΔGEM+/- obtained, in combination with the dramatic increase of Thy1-B220- cells from spleen and lymph nodes from ΔGEM+/- adult mice, the significant increase in Thy1+ and CD8+ from lymph nodes and the discernible decrease of spleenic CD4 T cells in ΔGEM+/- aged 5 months suggest that ΔGEM+/- mice are haploinsufficient. Similar results were obtained from the analysis of the GT knockout that we generated, using a gene trap mutagenesis approach.
GT heterozygote mice were crossed with heterozygote mice for BRG1 Knockout (BRG mice) and with heterozygote mice that overexpressed a dominant negative form of BAF57 (BAFΔN, BAF mice), so as to investigate whether there is a genetic interaction between Geminin and the two members of the SWI/SNF chromatin remodeling complex that have significant roles during development and differentiation of the immune system.
Upon conditional inactivation of Geminin’s gene in the immune system, using floxedTKneo and CD2-Cre mouse lines, that allowed the deletion of the gene from the DN stage and on, we were surprised to see that in the Geminin conditional knockout mice, thymic development was largely unaffected. On the contrary, spleenic cellularity from Geminin conditional knockout mice was fairly reduced, when compared to WT control littermates. Mitogenic stimulation with ConA of spleenic whole cell extract from Geminin conditional KO (FlTKneo/KO;CD2) and WT mice demonstrated that the mutant T cells were unable to divide.
Finally, we tried to overexpress human Geminin tagged with Green Fluorescent Protein (GFP) specifically in the immune system. This particular system would ensure high expression of the transgene mainly in T cells. We obtained founders for all of the cloned constructs, both with low and high copy transgene integration, but we were unable to detect GFP expression by FACS analysis.
Our results show that Geminin has a pivotal role during early mouse embryonic development, whereas tissue specific inactivation in the immune system leaves thymic development largely unaffected, whereas mature CD4 and CD8 T cells in the spleen are drastically reduced. Finally, Geminin seems to operate with SWI.SNF complex for the regulation of thymic CD4 and spleenic CD8.
|
65 |
Topoisomerase ll-a e Her-2 em tumores malignos de mama e de ovárioMano, Max Senna January 2006 (has links)
Introdução. O receptor epidérmico humano 2 (Her-2) e a topoisomerase-IIα (T2A) são dois marcadores biológicos importantes, ambos tendo um valor prognóstico e preditivo potencial em pacientes com tumores sólidos. A amplificação dos genes Her- 2 e T2A são eventos independentes, embora o último seja mais frequente em tumores com amplificação do Her-2 (34-90%), do que em tumores sem amplificação do Her-2 (5-10%). Existe uma melhor correlação entre amplificação e superexpressão do Her-2 no câncer de mama (CM) do que em outros tumores. No entanto, no CM, a correlação entre amplificação e superexpressão da T2A tem sido inconsistente, e existe uma carência de tais dados em outros tipos de tumores. A expressão da proteína T2A tem mostrado uma boa correlação com o índice de proliferação tumoral, particularmente no CM. Objetivos. Artigo 1: Sintetizar o conhecimento atual sobre a importância dos marcadores Her-2 e T2A nos tumores sólidos. Artigo 2: Investigar a prevalência de amplificação e superexpressão do Her-2 e da T2A, a correlação entre estas variáveis e a correlação entre as variáveis e estágio clínico, em amostras de câncer de ovário (CO) fixadas em parafina. Artigo 3: Investigar a prevalência de amplificação da T2A, assim como a correlação entre esta variável e a expressão da proteína T2A e do marcador de proliferação celular Ki-67, em amostras de CM fixadas em parafina, mostrando uma amplificação do Her-2. Métodos. Artigo 1: Os dados foram identificados através de busca em bases de dados eletrônicas (medline), livros de resumos de congressos e referências de artigos de revisão e originais. Artigo 2: 73 amostras de CO foram testadas para amplificação e superexpressão do Her-2 e T2A, por hibridização in situ fluorescente (FISH) e imuno-histoquímica (IHC), respectivamente. Artigo 3: 103 amostras de CM, com amplificação do Her-2, foram testadas para amplificação do gene T2A (por FISH) e superexpressão das proteínas T2A e Ki-67 (por IHC). Resultados. Artigo 2: Com base nos pontos de corte >1.5 e >2 (relação cópias/CEP17), as taxas de amplificação do Her-2 foram 15/64(23.4%) e 8/64(12.5%), versus 16/64(25%) e 5/64(7.8 %) para a T2A. Encontramos somente 3/72(4.2%) casos de superexpressão do Her-2(3+), contra 15/70(21.4%) para a T2A (marcagem em >10% das células). Foi observada uma modesta correlação entre amplificação e superexpressão da T2A (p= 0.01) e uma forte correlação entre amplificação da T2A e do Her-2, quando analisados como variáveis contínuas (p<0.001). A amplificação da T2A correlacionou-se com estágio FIGO avançado (p= 0.02). Artigo 3: Uma amplificação do gene T2A foi observada em 36.9%(38/103) dos casos. Os níveis de amplificação do Her-2 (número de cópias) não se correlacionaram com a amplificação da T2A. A porcentagem média de células positivas para a T2A (por IHC) foi de 5% e 10%, para casos T2A não-amplificados e amplificados, respectivamente. Uma correlação fraca, mas ainda significativa, foi observada entre amplificação do gene T2A e porcentagem de células T2A-positivas por IHC (Spearman=0.23, p=0.02); a correlação entre estas duas variáveis foi mais forte em tumores Ki-67 positivos. Conclusões. Artigo 2 : A avaliação da amplificação e da superexpressão do Her-2 e da T2A, por FISH e IHC, respectivamente, é realizável em amostras de CO. Foi observada uma boa correlação entre a amplificação dos genes Her-2 e T2A, mas a correlação entre amplificação do gene e superexpressão da proteína foi fraca para ambos marcadores. As taxas de amplificação dos genes Her-2 e T2A são mais elevadas quando não é realizada correção para o número de cópias do CEP17. Parece existir uma boa correlação entre amplificação da T2A e estágio clínico avançado. Estudos adicionais serão necessários para determinar o melhor ponto de corte para estes marcadores. Artigo 3: Contrariamente ao Her-2, a amplificação do gene T2A não parece necessariamente levar à superexpressão da proteína no CM. Outros fatores, como o índice de proliferação celular, podem interferir na síntese da proteína T2A. Embora a maioria dos casos de aberrações do gene T2A ocorram em tumores Her-2 positivos, os níveis de amplificação do Her-2 não se correlacionaram com a amplificação do gene T2A. / Background. The human epidermal receptor 2 (Her-2) and topoisomerase-IIα (T2A) are two important biomarkers, with potential prognostic and predictive value in patients with solid tumours. Her-2 and T2A gene amplification are separate events, although the latter is more frequently seen in Her-2 amplified (34-90%) than in Her-2 non-amplified (5-10%) tumours. There is a better correlation between Her-2 amplification and protein overexpression in breast cancer (BC) than in other tumour types. Nevertheless, there is a doubtful correlation between T2A amplification and overexpression in BC, with virtually no data available in other tumour types. In BC, the expression of the T2A protein has shown a good correlation with tumour proliferation rate. Objectives. Article 1: To summarise the available literature on Her-2 and T2A in solid tumours. Article 2: To investigate the prevalence of Her-2 and T2A amplification and overexpression, the correlation between these variables and with clinical stage, in paraffin-embedded samples of ovarian cancer (OC). Article 3: To investigate the prevalence of T2A amplification, as well as the correlation between this variable and the expression of T2A protein and the proliferation marker Ki-67, in paraffinembedded samples of Her-2 amplified BC. Methods. Article 1: The data were identified through search in electronic databases (medline), abstract books and references from review and original articles. Article 2: 73 samples of OC were tested for Her-2 and T2A amplification and overexpression, by fluorescence in situ hybridisation (FISH) and immunohistochemistry (IHC), respectively. Article 3: 103 samples of Her-2 amplified BC were tested for T2A amplification (by FISH) and overexpression (by IHC), and Ki-67 expression (by IHC). Results. Article 2: Based on cut-offs of ≥1.5 and ≥2 (ratio copies/CEP17), amplification rates for Her-2 were 15/64(23.4%) and 8/64(12.5%) versus 16/64(25%) and 5/64(7.8%) for T2A. We found only 3/72(4.2%) cases of Her-2 overexpression(3+) versus 15/70(21.4%) for T2A (staining in >10% of the cells). There was a modest correlation between T2A amplification and overexpression (p=0.01) and a strong correlation between T2A and Her-2 amplification when these markers were analysed as continuous variables (p<0.001). T2A amplification significantly correlated with advanced FIGO stage (p=0.02). Article 3: T2A gene amplification was observed in 36.9%(38/103) of the Her-2 amplified samples. Her-2 amplification level (i.e. copy number) was not predictive of T2A amplification. The median percentage of T2A positive cells for T2A non-amplified and amplified cases were 5% and 10%, respectively. A weak but still significant correlation was observed between T2A gene amplification level and percentage of positively stained cells (Spearman=0.23, p=0.02), the observed correlation being higher in patients with positive staining for Ki-67. Conclusions. Article 2: The assessment of Her-2 and T2A amplification and overexpression by FISH and IHC, respectively, is feasible in OC samples. There was a good correlation between Her-2 and T2A gene amplification, but the correlation between gene amplification and protein overexpression was poor for both markers. Amplification rates were higher in the absence of correction for the number of copies of the CEP17. Finally, we found a good correlation between T2A amplification and advanced disease stage. Further studies should aim to determine the optimal cut-offs for these markers. Article 3: Contrary to Her-2, T2A gene amplification does not always lead to protein overexpression in BC. Other factors, especially tumour proliferation rate, may interfere with the T2A protein status. Although the majority of the cases of T2A gene aberrations are seen in Her-2 positive tumours, the level of Her-2 amplification does not predict for T2A amplification.
|
66 |
Topoisomerase ll-a e Her-2 em tumores malignos de mama e de ovárioMano, Max Senna January 2006 (has links)
Introdução. O receptor epidérmico humano 2 (Her-2) e a topoisomerase-IIα (T2A) são dois marcadores biológicos importantes, ambos tendo um valor prognóstico e preditivo potencial em pacientes com tumores sólidos. A amplificação dos genes Her- 2 e T2A são eventos independentes, embora o último seja mais frequente em tumores com amplificação do Her-2 (34-90%), do que em tumores sem amplificação do Her-2 (5-10%). Existe uma melhor correlação entre amplificação e superexpressão do Her-2 no câncer de mama (CM) do que em outros tumores. No entanto, no CM, a correlação entre amplificação e superexpressão da T2A tem sido inconsistente, e existe uma carência de tais dados em outros tipos de tumores. A expressão da proteína T2A tem mostrado uma boa correlação com o índice de proliferação tumoral, particularmente no CM. Objetivos. Artigo 1: Sintetizar o conhecimento atual sobre a importância dos marcadores Her-2 e T2A nos tumores sólidos. Artigo 2: Investigar a prevalência de amplificação e superexpressão do Her-2 e da T2A, a correlação entre estas variáveis e a correlação entre as variáveis e estágio clínico, em amostras de câncer de ovário (CO) fixadas em parafina. Artigo 3: Investigar a prevalência de amplificação da T2A, assim como a correlação entre esta variável e a expressão da proteína T2A e do marcador de proliferação celular Ki-67, em amostras de CM fixadas em parafina, mostrando uma amplificação do Her-2. Métodos. Artigo 1: Os dados foram identificados através de busca em bases de dados eletrônicas (medline), livros de resumos de congressos e referências de artigos de revisão e originais. Artigo 2: 73 amostras de CO foram testadas para amplificação e superexpressão do Her-2 e T2A, por hibridização in situ fluorescente (FISH) e imuno-histoquímica (IHC), respectivamente. Artigo 3: 103 amostras de CM, com amplificação do Her-2, foram testadas para amplificação do gene T2A (por FISH) e superexpressão das proteínas T2A e Ki-67 (por IHC). Resultados. Artigo 2: Com base nos pontos de corte >1.5 e >2 (relação cópias/CEP17), as taxas de amplificação do Her-2 foram 15/64(23.4%) e 8/64(12.5%), versus 16/64(25%) e 5/64(7.8 %) para a T2A. Encontramos somente 3/72(4.2%) casos de superexpressão do Her-2(3+), contra 15/70(21.4%) para a T2A (marcagem em >10% das células). Foi observada uma modesta correlação entre amplificação e superexpressão da T2A (p= 0.01) e uma forte correlação entre amplificação da T2A e do Her-2, quando analisados como variáveis contínuas (p<0.001). A amplificação da T2A correlacionou-se com estágio FIGO avançado (p= 0.02). Artigo 3: Uma amplificação do gene T2A foi observada em 36.9%(38/103) dos casos. Os níveis de amplificação do Her-2 (número de cópias) não se correlacionaram com a amplificação da T2A. A porcentagem média de células positivas para a T2A (por IHC) foi de 5% e 10%, para casos T2A não-amplificados e amplificados, respectivamente. Uma correlação fraca, mas ainda significativa, foi observada entre amplificação do gene T2A e porcentagem de células T2A-positivas por IHC (Spearman=0.23, p=0.02); a correlação entre estas duas variáveis foi mais forte em tumores Ki-67 positivos. Conclusões. Artigo 2 : A avaliação da amplificação e da superexpressão do Her-2 e da T2A, por FISH e IHC, respectivamente, é realizável em amostras de CO. Foi observada uma boa correlação entre a amplificação dos genes Her-2 e T2A, mas a correlação entre amplificação do gene e superexpressão da proteína foi fraca para ambos marcadores. As taxas de amplificação dos genes Her-2 e T2A são mais elevadas quando não é realizada correção para o número de cópias do CEP17. Parece existir uma boa correlação entre amplificação da T2A e estágio clínico avançado. Estudos adicionais serão necessários para determinar o melhor ponto de corte para estes marcadores. Artigo 3: Contrariamente ao Her-2, a amplificação do gene T2A não parece necessariamente levar à superexpressão da proteína no CM. Outros fatores, como o índice de proliferação celular, podem interferir na síntese da proteína T2A. Embora a maioria dos casos de aberrações do gene T2A ocorram em tumores Her-2 positivos, os níveis de amplificação do Her-2 não se correlacionaram com a amplificação do gene T2A. / Background. The human epidermal receptor 2 (Her-2) and topoisomerase-IIα (T2A) are two important biomarkers, with potential prognostic and predictive value in patients with solid tumours. Her-2 and T2A gene amplification are separate events, although the latter is more frequently seen in Her-2 amplified (34-90%) than in Her-2 non-amplified (5-10%) tumours. There is a better correlation between Her-2 amplification and protein overexpression in breast cancer (BC) than in other tumour types. Nevertheless, there is a doubtful correlation between T2A amplification and overexpression in BC, with virtually no data available in other tumour types. In BC, the expression of the T2A protein has shown a good correlation with tumour proliferation rate. Objectives. Article 1: To summarise the available literature on Her-2 and T2A in solid tumours. Article 2: To investigate the prevalence of Her-2 and T2A amplification and overexpression, the correlation between these variables and with clinical stage, in paraffin-embedded samples of ovarian cancer (OC). Article 3: To investigate the prevalence of T2A amplification, as well as the correlation between this variable and the expression of T2A protein and the proliferation marker Ki-67, in paraffinembedded samples of Her-2 amplified BC. Methods. Article 1: The data were identified through search in electronic databases (medline), abstract books and references from review and original articles. Article 2: 73 samples of OC were tested for Her-2 and T2A amplification and overexpression, by fluorescence in situ hybridisation (FISH) and immunohistochemistry (IHC), respectively. Article 3: 103 samples of Her-2 amplified BC were tested for T2A amplification (by FISH) and overexpression (by IHC), and Ki-67 expression (by IHC). Results. Article 2: Based on cut-offs of ≥1.5 and ≥2 (ratio copies/CEP17), amplification rates for Her-2 were 15/64(23.4%) and 8/64(12.5%) versus 16/64(25%) and 5/64(7.8%) for T2A. We found only 3/72(4.2%) cases of Her-2 overexpression(3+) versus 15/70(21.4%) for T2A (staining in >10% of the cells). There was a modest correlation between T2A amplification and overexpression (p=0.01) and a strong correlation between T2A and Her-2 amplification when these markers were analysed as continuous variables (p<0.001). T2A amplification significantly correlated with advanced FIGO stage (p=0.02). Article 3: T2A gene amplification was observed in 36.9%(38/103) of the Her-2 amplified samples. Her-2 amplification level (i.e. copy number) was not predictive of T2A amplification. The median percentage of T2A positive cells for T2A non-amplified and amplified cases were 5% and 10%, respectively. A weak but still significant correlation was observed between T2A gene amplification level and percentage of positively stained cells (Spearman=0.23, p=0.02), the observed correlation being higher in patients with positive staining for Ki-67. Conclusions. Article 2: The assessment of Her-2 and T2A amplification and overexpression by FISH and IHC, respectively, is feasible in OC samples. There was a good correlation between Her-2 and T2A gene amplification, but the correlation between gene amplification and protein overexpression was poor for both markers. Amplification rates were higher in the absence of correction for the number of copies of the CEP17. Finally, we found a good correlation between T2A amplification and advanced disease stage. Further studies should aim to determine the optimal cut-offs for these markers. Article 3: Contrary to Her-2, T2A gene amplification does not always lead to protein overexpression in BC. Other factors, especially tumour proliferation rate, may interfere with the T2A protein status. Although the majority of the cases of T2A gene aberrations are seen in Her-2 positive tumours, the level of Her-2 amplification does not predict for T2A amplification.
|
67 |
Flora??o precoce em cana-de-a??car - um estudo utilizando ferramentas de an?lise in silico e prote?micaDuarte, Maria Ang?lica Gaag 26 February 2009 (has links)
Made available in DSpace on 2014-12-17T15:18:10Z (GMT). No. of bitstreams: 1
MariaAGD.pdf: 3831855 bytes, checksum: 0abe0a10e359f22bab7ed834fa8e296a (MD5)
Previous issue date: 2009-02-26 / Sugarcane is one of the most important products of the world and Brazil is responsible for 25 % of the world production. One problem of this culture at northeast of Brazil is the early flowering. In our laboratory, it has been made before four
subtractive libraries using early and late flowering genotypes in order to identify messages related to the flowering process. In this work, two cDNAs were chosen to make in silico analysis and overexpression constructs. Another approach to
understand the flowering process in sugarcane was to use proteomic tools. First, the protocol for protein extraction using apical meristem was set up. After that, these proteins were separated on two bidimensional gels. It was possible to observe some difference for some regions of these gels as well as some proteins that can be found in all conditions. The next step, spots will be isolated and sequence on MS
spectrometry in order to understand this physiological process in sugarcane / A cana-de-a??car ? uma das mais importantes culturas mundiais e atualmente o Brasil representa um dos maiores produtores de cana-de-a??car no ranque mundial. Sabendo-se da import?ncia da cana-de-a??car nos dias atuais, principalmente em rela??o ao biocombust?vel e do problema causado pela flora??o precoce a esta cultura na regi?o Nordeste, foi realizada uma an?lise in silico de dois cDNAs:, 14-3-3 like protein e Protein kinase C inhibitor-like (PKCI), envolvidos no processo de flora??o da cana-de-a??car, utilizando ferramentas gen?micas. Foi escolhido o cDNA PKCI para a constru??o de cassetes de super-express?o de modo a ser caracterizado o papel deste cDNA no processo de flora??o. Outra abordagem utilizada nesse trabalho foi de analisar prote?nas totais de ?pices meristem?ticos de
variedades precoce e tardia em g?is uni e bidimensionais. Os resultados mostraram que existem algumas prote?nas que podem ser caracter?sticas de uma das variedades, e em outras foi observado uma express?o diferencial
|
68 |
Análise funcional do fator de transcrição DREB6A de feijão (Phaseolus vulgaris L.) pela superexpressão em Arabidopsis thaliana / Functional analysis of the transcription factor DREB6A from common bean (Phaseolus vulgaris L.) by overexpression in Arabidopsis thalianaAna Carolina Vieira Zakir Pereira 03 June 2014 (has links)
Estresses abióticos como seca, alta salinidade e baixas temperaturas, afetam o crescimento e a produtividade em culturas de interesse comercial como o feijoeiro comum. Proteínas DREB (Dehydration Responsive Element Binding) são fatores de transcrição que regulam genes específicos envolvidos na tolerância ao estresse abiótico. Para determinar como as plantas toleram condições ambientais adversas, variedades tolerantes, biologia molecular e bioinformática podem ser aplicadas para identificar e caracterizar genes que controlam mecanismos de adaptação a estresses. Baseado nas informações disponíveis nos bancos de dados públicos, a sequência da Orf completa do gene Phvul.009G029600.1| PACid:27146455 contendo 1062 pb foi encontrada e usada para o desenho dos primers e para o sequenciamento. A nova sequência é muito similar ao AtRAP2.4 e foi nomeada como PvDREB6A, segundo a análise filogenética. Ferramentas de predição mostraram que a sequência apresenta 354 aminoácidos e possui uma cópia do domínio AP2, que se dobra em uma estrutura com três ?-folhas e uma ?-hélice apresentando resíduos importantes e motivos específicos de reconhecimento e de ligação ao DNA. Além disso, um peptídeo trânsito foi detectado na porção N-terminal com um sítio de clivagem no resíduo 52. A interação deste fator de transcrição com seu domínio de ligação ao DNA foi validada por Electro Mobility Shift Assay (EMSA). A localização subcelular da proteína foi realizada e expressão da Green Fluorescent Proteín (GFP) foi detectada no núcleo. A transformação genética para a superexpressão do gene PvDREB6A em plantas de Arabidopsis thaliana Columbia-0 e mutantes nocaute para o gene AtRAP2.4 (Salk_020767C) foi realizada. Quatro eventos com cópia única e melhor expressão do gene PvDREB6A denominados Col-0/pFEC2.1 #1, Salk_020767C/pFEC2.1 #13.1, Salk_020767C/ pFEC2.1 #19.7 e Salk_020767C/ pFEC2.1 #23.7, foram selecionados. O evento Salk_020767C/pFEC2.1 #23.7 mostrou melhor expressão do gene PvDREB6A e foi visualizado sob luz UV. A análise funcional revelou que as plantas transgênicas submetidas ao déficit hídrico, à alta salinidade e ao frio, apresentaram maior taxa de sobrevivência. Plantas transgênicas superexpressando o gene PvDREB6A apresentaram menor taxa de desidratação e de vazamento de eletrólitos quando submetidas a estresses abióticos. Uma análise da expressão de genes relacionados à tolerância foi conduzida. A quantificação revelou que a expressão de 18 genes: AtDC1.2, AtUSP, AtKIN1, AtERF69, AtGolS3, AtMT2A, AtCAP160, AtNTR1.7, AtGPR7, AtPDC2, AtLTI78, AtCOR15a, AtCOR15b, AtCOR47, AtCOR413, AtLEA6, AtLEA9 e AtLEA14, relacionados a tolerância a seca, sal e frio foram up-regulated devido à superexpressão do gene PvDREB6A de feijoeiro nas plantas transgênicas / Abiotic stresses like drought, high salinity and low temperatures affect growth and productivity in crops of economic interest such as common bean. DREB (Dehydration Responsive Element Binding) proteins are transcription factors that activate specific genes involved in tolerance to abiotic stress. To generate new information on the research for drought and other abiotic stresses, tolerant varieties, molecular biology and bioinformatics can be applied to identify and characterize genes that control plant defense and adaptation mechanisms to water deprivation, to excessive salt and to high/low temperature. Based on public databases, a common bean DREB sequence was found and an in silico study was carried out. A complete Orf sequence Phvul.009G029600.1 |PACid:27146455 containing 1062 bp was found and used for primer design and sequencing. The new sequence was very similar to AtRAP2.4 and named as PvDREB6A, according to phylogenetic analysis. Prediction tools showed that the deduced 354 aa sequence has one copy of the AP2 domain, folding in a three ?-sheets and one ?-helix structure, and presenting important residues and motifs for DNA contacting and binding specificity. In addition, a chloroplast transit peptide was detected at the N-terminal region with cleavage site in the 52 residue. Binding activity of this transcription factor was validated by Electro Mobility Shift Assay (EMSA). Subcellular localization was verified by transient expression of PvDREB6A::GFP in Nicotiana benthamiana and the expression of GFP was detected at the nucleus. Genetic transformation for overexpression of PvDREB6A gene in Arabidopsis thaliana wild type and knockout mutant for AtRAP2.4 gene was conducted. Four single copy events with better expression of the PvDREB6A named Col-0/pFEC2.1 #1, Salk_020767C/pFEC2.1 #13.1, Salk_020767C/pFEC2.1 #19.7 and Salk_020767C/pFEC2.1 #23.7 were selected. The event Salk_020767C/pFEC2.1 #23.7 showed the best expression of PvDREB6A and was visualized under UV light. Functional analysis, revealed that transgenic plants under water deficit, high salt, and cold showed higher survival rate. Transgenic plants overexpressing the PvDREB6A exhibited lower water loss rate and electrolyte leakage rate under abiotic stress. A gene expression analysis with tolerant-related genes was conduted. The quantification revealed that 18 genes, AtDC1.2, AtUSP, AtKIN1, AtERF69, AtGolS3, AtMT2A, AtCAP160, AtNTR1.7, AtGPR7, AtPDC2, AtLTI78, AtCOR15a, AtCOR15b, AtCOR47, AtCOR413, AtLEA6, AtLEA9 e AtLEA14, related to drought, salt and cold tolerance, were up-regulated due to the overexpression of PvDREB6A from common bean in the transgenic plants
|
69 |
Topoisomerase ll-a e Her-2 em tumores malignos de mama e de ovárioMano, Max Senna January 2006 (has links)
Introdução. O receptor epidérmico humano 2 (Her-2) e a topoisomerase-IIα (T2A) são dois marcadores biológicos importantes, ambos tendo um valor prognóstico e preditivo potencial em pacientes com tumores sólidos. A amplificação dos genes Her- 2 e T2A são eventos independentes, embora o último seja mais frequente em tumores com amplificação do Her-2 (34-90%), do que em tumores sem amplificação do Her-2 (5-10%). Existe uma melhor correlação entre amplificação e superexpressão do Her-2 no câncer de mama (CM) do que em outros tumores. No entanto, no CM, a correlação entre amplificação e superexpressão da T2A tem sido inconsistente, e existe uma carência de tais dados em outros tipos de tumores. A expressão da proteína T2A tem mostrado uma boa correlação com o índice de proliferação tumoral, particularmente no CM. Objetivos. Artigo 1: Sintetizar o conhecimento atual sobre a importância dos marcadores Her-2 e T2A nos tumores sólidos. Artigo 2: Investigar a prevalência de amplificação e superexpressão do Her-2 e da T2A, a correlação entre estas variáveis e a correlação entre as variáveis e estágio clínico, em amostras de câncer de ovário (CO) fixadas em parafina. Artigo 3: Investigar a prevalência de amplificação da T2A, assim como a correlação entre esta variável e a expressão da proteína T2A e do marcador de proliferação celular Ki-67, em amostras de CM fixadas em parafina, mostrando uma amplificação do Her-2. Métodos. Artigo 1: Os dados foram identificados através de busca em bases de dados eletrônicas (medline), livros de resumos de congressos e referências de artigos de revisão e originais. Artigo 2: 73 amostras de CO foram testadas para amplificação e superexpressão do Her-2 e T2A, por hibridização in situ fluorescente (FISH) e imuno-histoquímica (IHC), respectivamente. Artigo 3: 103 amostras de CM, com amplificação do Her-2, foram testadas para amplificação do gene T2A (por FISH) e superexpressão das proteínas T2A e Ki-67 (por IHC). Resultados. Artigo 2: Com base nos pontos de corte >1.5 e >2 (relação cópias/CEP17), as taxas de amplificação do Her-2 foram 15/64(23.4%) e 8/64(12.5%), versus 16/64(25%) e 5/64(7.8 %) para a T2A. Encontramos somente 3/72(4.2%) casos de superexpressão do Her-2(3+), contra 15/70(21.4%) para a T2A (marcagem em >10% das células). Foi observada uma modesta correlação entre amplificação e superexpressão da T2A (p= 0.01) e uma forte correlação entre amplificação da T2A e do Her-2, quando analisados como variáveis contínuas (p<0.001). A amplificação da T2A correlacionou-se com estágio FIGO avançado (p= 0.02). Artigo 3: Uma amplificação do gene T2A foi observada em 36.9%(38/103) dos casos. Os níveis de amplificação do Her-2 (número de cópias) não se correlacionaram com a amplificação da T2A. A porcentagem média de células positivas para a T2A (por IHC) foi de 5% e 10%, para casos T2A não-amplificados e amplificados, respectivamente. Uma correlação fraca, mas ainda significativa, foi observada entre amplificação do gene T2A e porcentagem de células T2A-positivas por IHC (Spearman=0.23, p=0.02); a correlação entre estas duas variáveis foi mais forte em tumores Ki-67 positivos. Conclusões. Artigo 2 : A avaliação da amplificação e da superexpressão do Her-2 e da T2A, por FISH e IHC, respectivamente, é realizável em amostras de CO. Foi observada uma boa correlação entre a amplificação dos genes Her-2 e T2A, mas a correlação entre amplificação do gene e superexpressão da proteína foi fraca para ambos marcadores. As taxas de amplificação dos genes Her-2 e T2A são mais elevadas quando não é realizada correção para o número de cópias do CEP17. Parece existir uma boa correlação entre amplificação da T2A e estágio clínico avançado. Estudos adicionais serão necessários para determinar o melhor ponto de corte para estes marcadores. Artigo 3: Contrariamente ao Her-2, a amplificação do gene T2A não parece necessariamente levar à superexpressão da proteína no CM. Outros fatores, como o índice de proliferação celular, podem interferir na síntese da proteína T2A. Embora a maioria dos casos de aberrações do gene T2A ocorram em tumores Her-2 positivos, os níveis de amplificação do Her-2 não se correlacionaram com a amplificação do gene T2A. / Background. The human epidermal receptor 2 (Her-2) and topoisomerase-IIα (T2A) are two important biomarkers, with potential prognostic and predictive value in patients with solid tumours. Her-2 and T2A gene amplification are separate events, although the latter is more frequently seen in Her-2 amplified (34-90%) than in Her-2 non-amplified (5-10%) tumours. There is a better correlation between Her-2 amplification and protein overexpression in breast cancer (BC) than in other tumour types. Nevertheless, there is a doubtful correlation between T2A amplification and overexpression in BC, with virtually no data available in other tumour types. In BC, the expression of the T2A protein has shown a good correlation with tumour proliferation rate. Objectives. Article 1: To summarise the available literature on Her-2 and T2A in solid tumours. Article 2: To investigate the prevalence of Her-2 and T2A amplification and overexpression, the correlation between these variables and with clinical stage, in paraffin-embedded samples of ovarian cancer (OC). Article 3: To investigate the prevalence of T2A amplification, as well as the correlation between this variable and the expression of T2A protein and the proliferation marker Ki-67, in paraffinembedded samples of Her-2 amplified BC. Methods. Article 1: The data were identified through search in electronic databases (medline), abstract books and references from review and original articles. Article 2: 73 samples of OC were tested for Her-2 and T2A amplification and overexpression, by fluorescence in situ hybridisation (FISH) and immunohistochemistry (IHC), respectively. Article 3: 103 samples of Her-2 amplified BC were tested for T2A amplification (by FISH) and overexpression (by IHC), and Ki-67 expression (by IHC). Results. Article 2: Based on cut-offs of ≥1.5 and ≥2 (ratio copies/CEP17), amplification rates for Her-2 were 15/64(23.4%) and 8/64(12.5%) versus 16/64(25%) and 5/64(7.8%) for T2A. We found only 3/72(4.2%) cases of Her-2 overexpression(3+) versus 15/70(21.4%) for T2A (staining in >10% of the cells). There was a modest correlation between T2A amplification and overexpression (p=0.01) and a strong correlation between T2A and Her-2 amplification when these markers were analysed as continuous variables (p<0.001). T2A amplification significantly correlated with advanced FIGO stage (p=0.02). Article 3: T2A gene amplification was observed in 36.9%(38/103) of the Her-2 amplified samples. Her-2 amplification level (i.e. copy number) was not predictive of T2A amplification. The median percentage of T2A positive cells for T2A non-amplified and amplified cases were 5% and 10%, respectively. A weak but still significant correlation was observed between T2A gene amplification level and percentage of positively stained cells (Spearman=0.23, p=0.02), the observed correlation being higher in patients with positive staining for Ki-67. Conclusions. Article 2: The assessment of Her-2 and T2A amplification and overexpression by FISH and IHC, respectively, is feasible in OC samples. There was a good correlation between Her-2 and T2A gene amplification, but the correlation between gene amplification and protein overexpression was poor for both markers. Amplification rates were higher in the absence of correction for the number of copies of the CEP17. Finally, we found a good correlation between T2A amplification and advanced disease stage. Further studies should aim to determine the optimal cut-offs for these markers. Article 3: Contrary to Her-2, T2A gene amplification does not always lead to protein overexpression in BC. Other factors, especially tumour proliferation rate, may interfere with the T2A protein status. Although the majority of the cases of T2A gene aberrations are seen in Her-2 positive tumours, the level of Her-2 amplification does not predict for T2A amplification.
|
70 |
CLONAGEM E EXPRESSÃO DO GENE xynB3 QUE CODIFICA A β-XILOSIDASE III NA BACTÉRIA AQUÁTICA Caulobacter crescentus / CLONING AND EXPRESSION OF xynB3 GENE CODING FOR -XYLOSIDASE III IN Caulobacter crescentus AQUATIC BACTERIUMBosetto, Adilson 10 March 2015 (has links)
Made available in DSpace on 2017-07-10T19:23:52Z (GMT). No. of bitstreams: 1
Dissertacao_ Adilson Bosetto 2015 PDF.pdf: 2419034 bytes, checksum: 3fdc9e711199e04fe0746f89b07c4bea (MD5)
Previous issue date: 2015-03-10 / The application of enzymes in industrial processes, in its broad sense, has shown the market evolution for innovative alternatives for preserving the environment. Brazil has a great potential to develop some technologies, which allow the use of such materials as substratum for products with higher added value, due to the large amount of lignocellulose as waste that comes from agriculture. Therefore, the analysis of genes expression related to microbial degradation of plant cell wall has caught the researchers attention, mainly because it is associated to the possibility of controlled large-scale synthesis of enzymes applied in biofuel production. In this context, the Gram-negative bacterium C. crescentus is found as a promising microorganism for biotechnological exploitation due to its ability on degrading xylan, the major component of plant hemicellulose. There are several genes in the bacterial genome that codify to Xylanases and β-Xylosidases. In order to purify and biochemically characterize the β-Xylosidase III protein of C. crescentus, xynB3 gene (CCNA_00856) that contains 1,623 nucleotides and encodes a protein with conserved domains of β-Xylosidase with 540 amino acid residues has been studied. Therefore, xynB3 gene was isolated from genomic DNA of C. crescentus NA1000 by Polymerase Chain Reaction (PCR) using specific primers. The single amplification product was cloned into pJet1.2Blunt vector in non-cohesive sites and reintroduced in vector of pTrcHisA expression within the reading frame to produce a histidine tag at the amino-terminus area of fusion protein. The obtained construction was denominated pTrcHis-xynB3 and the confirmation of its gene identification was figured out by the DNA sequence after insertion into the TOP10 E. coli strain and subsequent experimental tests of expression in different temperature of growth, IPTG concentrations and induction times. The recombinant protein was overexpressed into inclusion bodies, thus, in a non-soluble form. Different induction and purification protocols were used to obtain the β-xylosidase III pure of C. crescentus, in native or non-native form. However, assays of enzymatic activity with different substrates neither demonstrated β-xylosidase activity nor detectable levels of the protein. These results suggest that the enzyme was not active during the assays, due its expression in inclusion bodies. This suggests that this protein may have a toxic effect on E. coli when expressed at high levels. Thus, this trial contributes to additional data about the xylanolytic complex concerning the aquatic bacterium C. crescentus. / A utilização de enzimas em processos industriais, no seu sentido mais amplo, demonstra a evolução do mercado em relação a alternativas inovadoras de preservação do meio ambiente. Devido à grande quantidade de material lignocelulósico residuário, proveniente da agricultura, o Brasil é um país com elevado potencial para o desenvolvimento de tecnologias que possibilitem a utilização desses materiais como substrato para produtos de maior valor agregado. Dessa forma, o estudo da expressão de genes microbianos relacionados com a degradação da parede celular vegetal tem despertado a atenção de pesquisadores, principalmente pelo fato de estar relacionado com a possibilidade de síntese controlada e em larga escala de enzimas utilizadas na produção de biocombustíveis. Neste contexto, a bactéria gram-negativa Caulobacter crescentus encontra-se como um microrganismo promissor para a exploração biotecnológica em função da capacidade que tem de degradar o xilano, principal componente hemicelulósico das plantas. Essa bactéria contém em seu genoma vários genes que codificam para xilanases e β-xilosidases. Dentre eles o gene xynB3 (CCNA_00856), que apresenta 1623 nucleotídeos e codifica uma proteína contendo domínios conservados de β-xilosidase, com 540 resíduos de aminoácidos, denominada neste trabalho como β-xilosidase III de C. crescentus. Com o objetivo de possibilitar em estudos futuros a caracterização bioquímica dessa proteína, foi estudado o gene xynB3. Para isso, xynB3 foi isolado a partir do DNA genômico de C. crescentus NA1000 por Reação em Cadeia da Polimerase (PCR) usando oligonucleotídeos específicos. O único produto de amplificação foi clonado no vetor pJet1.2blunt em sítios não coesivos e reintroduzido no vetor de expressão pTrcHisA dentro do quadro de leitura para a produção de uma cauda de histidinas na região amino-terminal da proteína de fusão. A construção obtida foi denominada pTricHis-xynB3 e após confirmação da identidade da mesma por sequenciamento de DNA foi inserida na cepa TOP10 de Escherichia coli e submetida a ensaios experimentais de expressão com diferentes temperaturas de crescimento, concentrações de IPTG e tempos de indução. A proteína recombinante foi super-expressa em corpos de inclusão, portanto, em uma forma não solúvel. Diferentes protocolos de indução e purificação foram empregados para obtenção da β-xilosidase III de C. crescentus pura, em forma nativa ou não nativa. Entretanto, nos ensaios de atividade enzimática, com diferentes substratos, foram obtidos níveis de atividade de β-xilosidase não detectáveis pelas ferramentas utilizadas. Esses resultados sugerem que a enzima não se mostrou ativa durante os ensaios, em função da formação de corpos de inclusão. Isso leva a crer que essa proteína pode apresentar efeito tóxico para E. coli quando expressa em níveis elevados. Assim, este trabalho contribui com dados adicionais a cerca do complexo xilanolítico da bactéria aquática C. crescentus.
|
Page generated in 0.0941 seconds